-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Allena Pharmaceuticals (NASDAQ:ALNAQ) and Humacyte (NASDAQ:HUMA) Head to Head Survey
Allena Pharmaceuticals (NASDAQ:ALNAQ) and Humacyte (NASDAQ:HUMA) Head to Head Survey
Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) and Humacyte (NASDAQ:HUMA – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.
Earnings and Valuation
This table compares Allena Pharmaceuticals and Humacyte's revenue, earnings per share and valuation.
Get Allena Pharmaceuticals alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Allena Pharmaceuticals | N/A | N/A | -$48.66 million | N/A | N/A |
Humacyte | $1.26 million | 225.88 | -$26.48 million | $0.32 | 8.63 |
Humacyte has higher revenue and earnings than Allena Pharmaceuticals.
Institutional & Insider Ownership
7.3% of Allena Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.1% of Humacyte shares are owned by institutional investors. 3.7% of Allena Pharmaceuticals shares are owned by company insiders. Comparatively, 25.0% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.Analyst Ratings
This is a summary of recent ratings and recommmendations for Allena Pharmaceuticals and Humacyte, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Allena Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Humacyte | 1 | 0 | 1 | 0 | 2.00 |
Humacyte has a consensus target price of $5.88, indicating a potential upside of 112.86%. Given Humacyte's higher probable upside, analysts clearly believe Humacyte is more favorable than Allena Pharmaceuticals.
Risk and Volatility
Allena Pharmaceuticals has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.
Profitability
This table compares Allena Pharmaceuticals and Humacyte's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Allena Pharmaceuticals | N/A | -287.46% | -146.58% |
Humacyte | 1,971.30% | -74.59% | -35.49% |
Summary
Humacyte beats Allena Pharmaceuticals on 9 of the 10 factors compared between the two stocks.
About Allena Pharmaceuticals
(Get Rating)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
About Humacyte
(Get Rating)
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) and Humacyte (NASDAQ:HUMA – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.
阿列納製藥(納斯達克:ALNAQ-GET評級)和Humacyte(納斯達克:HUMA-GET評級)都是小盤醫療公司,但哪一家更好?我們將根據兩家公司的收益、估值、風險、機構所有權、股息、盈利能力和分析師的建議來比較它們的實力。
Earnings and Valuation
收益和估值
This table compares Allena Pharmaceuticals and Humacyte's revenue, earnings per share and valuation.
該表格比較了Allena製藥公司和Humacyte的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Allena Pharmaceuticals | N/A | N/A | -$48.66 million | N/A | N/A |
Humacyte | $1.26 million | 225.88 | -$26.48 million | $0.32 | 8.63 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
Allena製藥公司 | 不適用 | 不適用 | -4,866萬元 | 不適用 | 不適用 |
Humacyte | 126萬美元 | 225.88 | -2,648萬美元 | $0.32 | 8.63 |
Humacyte has higher revenue and earnings than Allena Pharmaceuticals.
Humacyte的收入和收益高於Allena製藥公司。
Institutional & Insider Ownership
機構與內部人持股
Analyst Ratings
分析師評級
This is a summary of recent ratings and recommmendations for Allena Pharmaceuticals and Humacyte, as reported by MarketBeat.com.
據MarketBeat.com報道,這是對Allena製藥公司和Humacyte公司最近評級和推薦的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Allena Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Humacyte | 1 | 0 | 1 | 0 | 2.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
Allena製藥公司 | 0 | 0 | 0 | 0 | 不適用 |
Humacyte | 1 | 0 | 1 | 0 | 2.00 |
Humacyte has a consensus target price of $5.88, indicating a potential upside of 112.86%. Given Humacyte's higher probable upside, analysts clearly believe Humacyte is more favorable than Allena Pharmaceuticals.
Humacyte的普遍目標價為5.88美元,表明潛在上行空間為112.86%。鑑於Humacyte更有可能上行,分析師顯然認為Humacyte比Allena PharmPharmticals更有利。
Risk and Volatility
風險和波動性
Allena Pharmaceuticals has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.
Allena PharmPharmticals的貝塔係數為1.34,這表明其股價的波動性比標準普爾500指數高34%。相比之下,Humacyte的貝塔係數為0.92,這表明其股價的波動性比標準普爾500指數低8%。
Profitability
盈利能力
This table compares Allena Pharmaceuticals and Humacyte's net margins, return on equity and return on assets.
此表比較了Allena製藥公司和Humacyte公司的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Allena Pharmaceuticals | N/A | -287.46% | -146.58% |
Humacyte | 1,971.30% | -74.59% | -35.49% |
淨利潤率 | 股本回報率 | 資產回報率 | |
Allena製藥公司 | 不適用 | -287.46% | -146.58% |
Humacyte | 1,971.30% | -74.59% | -35.49% |
Summary
摘要
Humacyte beats Allena Pharmaceuticals on 9 of the 10 factors compared between the two stocks.
Humacyte在兩隻股票比較的10個因素中有9個擊敗了Allena PharmPharmticals。
About Allena Pharmaceuticals
關於Allena製藥公司
(Get Rating)
(獲取評級)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Allena製藥公司是一家生物製藥公司,在美國發現、開發和商業化口服酶療法,用於治療罕見和嚴重的代謝以及腎臟疾病患者。它的主要候選產品是ALLN-346,這是一種新型的尿酸降解酶,適用於晚期慢性腎臟疾病中的高尿酸血癥和痛風患者。該公司成立於2011年,總部設在馬薩諸塞州牛頓市。2022年9月2日,Allena製藥公司根據破產法第11章向美國特拉華州地區破產法院提交了自願重組請願書。
About Humacyte
關於Humacyte
(Get Rating)
(獲取評級)
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Humacyte,Inc.致力於開發和製造現成的、可植入的和生物工程的人體組織,用於治療多個治療領域中各種解剖位置的疾病和狀況。該公司利用其專有的科學技術平臺來設計和製造人類脱細胞血管(HAVS)。它的研究用HAVs可以很容易地移植到任何患者體內,而不會引起異物反應或導致免疫排斥反應。該公司正在開發一系列HAVs,目標是血管修復、重建和替代市場,包括血管創傷;用於血液透析的動靜脈通路;外周動脈疾病;以及冠狀動脈旁路移植,以及開發用於兒科心臟手術和細胞治療提供的HAVs,包括治療1型糖尿病的胰島細胞移植。該公司成立於2004年,總部設在北卡羅來納州的達勒姆。
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Allena PharmPharmticals Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Allena製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧